Abstract:Background Ovarian cancer, a fatal gynecological malignancy, is primarily managed through surgery and chemotherapy. However, a significant challenge arises as patients frequently experience relapse due to chemotherapy resistance. This study delves into the complex functions and underlying mechanisms of macrophages in chemotherapy resistance in ovarian cancer. Method The single-cell transcriptome sequencing data of ovarian cancer with or without chemotherapy were analyzed. Then, corresponding cell types were identified, and macrophages were extracted from all cells. Following the standardized single-cell analysis using the Seurat package, 15 distinct macrophage clusters were found and differentially expressed genes among them were analyzed. Moreover, their association with chemotherapy resistance was explored through cell proportions and gene expression. Result In the single-cell transcriptomic analysis of ovarian cancer tissues before and after chemotherapy, the cellular proportion of CXCL5 + macrophages, THBS1 + macrophages, and MMP9 + macrophages were significantly increased following chemotherapy. Further investigation revealed that these macrophage subpopulations upregulated the expression of multiple pro-tumorigenic angiogenic or invasive factors, in addition to CXCL5, THBS1, and MMP9, including CTSL, CXCL1, and CCL18. Finally, pathway enrichment analysis revealed the significant activation of signaling pathways, such as NOD-like receptor, MAPK, and TNF in these macrophage subpopulations, which provides direction for studying the mechanism of these subpopulations. Conclusion CXCL5 + , THBS1 + , and MMP9 + macrophage subpopulations exhibit an increased cellular prevalence post-chemotherapy and pro-tumorigenic molecular expression profiles, suggesting a close association with chemoresistance in ovarian cancer. These findings contribute to our understanding of the roles and mechanisms of macrophages in ovarian cancer chemoresistance, providing a theoretical basis and direction for the development of therapies targeting macrophages in overcoming ovarian cancer chemoresistance.

Tumor‐associated macrophage‐targeted therapeutics in ovarian cancer

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy

The promising role of tumor-associated macrophages in the treatment of cancer

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma

Tumor-Associated Macrophages: Recent Insights and Therapies

Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy

Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

Single-cell transcriptome analysis of macrophage subpopulations contributing to chemotherapy resistance in ovarian cancer

Tumor-Associated Macrophages (tams): A Critical Activator in Ovarian Cancer Metastasis

Role of macrophages in tumor progression and therapy (Review)

Signatures of tumor-associated macrophages correlate with treatment response in ovarian cancer patients

Ott_a_216355 8687..8699

The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors

Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review)

Macrophages as potential targets in gene therapy for cancer treatment